Learn More
Description
- Broad-Spectrum Inhibition of Common Eukaryotic RNases
- Native, recombinant and oxidation-resistant forms available
- Does not inhibit SP6, T7 or T3 RNA Polymerase; GoScript™ Reverse Transcriptase, AMV or M-MLV Reverse Transcriptase; or Taq DNA polymerase.
- Use in many downstream assays: Inhibits a broad spectrum of eukaryotic RNases over a wide pH range (pH 5-8)
- Maintains inhibitory activity over a wide temperature range
- 1U.S. Patents 4,966,964, 5,019,556, and 5,266,687; Australian Patents 616881 and 641261, are exclusively licensed to Promega Corporation.
- U.S. Patent 5,552,302, Australian Patent 646803.
Specifications
Specifications
| Concentration | 20 to 40 U/μL |
| Formulation | Amount of RNasin™ RNase inhibitor required to inhibit the activity of 5ng of RNase A by 50%, activity is measured by the inhibition of hydrolysis of Cytidine 2,3'-cyclic Monophosphate by RNase A |
| For Use With (Application) | RT-PCR, protection of mRNA in cDNA synthesis reactions, in-vitro transcription/translation, Increase yield and activity of polysomes, improvement of in-vitro virus replication, improvement of RNA translation in homologous systems, performing RNase-free Antibody staining, enhancement of RNA yields from Riboprobe™ system RNA synthesis reactions |
| Quantity | 10,000 U |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.